ArticleCancers2020
Article in Cancers, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 28 citations in OpenAlex.
- Prognostic impact of RAS mutation on papillary thyroid carcinoma: a systematic review and meta-analysis.Thyroid research · 2025Review
- The effect of TERT promoter mutation on predicting meningioma outcomes: a multi-institutional cohort analysis.The Lancet. Oncology · 2025Article
- The impact of C216T and hot spot mutations of the TERT promoter on the clinicopathologic characteristics and S100A10 expression in papillary thyroid carcinoma: a comparative study.Diagnostic pathology · 2025Article
- Molecular Diagnosis of Thyroid Nodules Using Next-Generation Sequencing in the Chinese Population.International journal of endocrinology · 2025Article
- Using deep learning to decipher the impact of telomerase promoter mutations on the dynamic metastatic morpholome.PLoS computational biology · 2024Article
- Article
- Subcentimetric papillary thyroid carcinoma with extensive lymph node and brain metastasis: case report and review of literature.Endocrinology, diabetes & metabolism case reports · 2023Article
- Genomic and transcriptomic analyses of thyroid cancers identify DICER1 somatic mutations in adult follicular-patterned RAS-like tumors.Frontiers in endocrinology · 2023Article
- Article
- The Specifically Androgen-Regulated Gene (SARG) Promotes Papillary Thyroid Carcinoma (PTC) Lymphatic Metastasis Through Vascular Endothelial Growth Factor C (VEGF-C) and VEGF Receptor 3 (VEGFR-3) Axis.Frontiers in oncology · 2022Article
- Novel Inhibitor-Based Therapies for Thyroid Cancer-An Update.International journal of molecular sciences · 2021Review
- Analysis of the Role of FRMD5 in the Biology of Papillary Thyroid Carcinoma.International journal of molecular sciences · 2021Article
- BRAF Inhibitors Induce Feedback Activation of RAS Pathway in Thyroid Cancer Cells.International journal of molecular sciences · 2021Article
- EmergingGenes · 2020Review
- Review
- Differences in Gene Expression Profile of Primary Tumors in Metastatic and Non-Metastatic Papillary Thyroid Carcinoma-Do They Exist?International journal of molecular sciences · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 1 institution in 1 country.
Funding
Abstract
backgroundTelomerase reverse transcriptase promoter (
methodsThe studied cohort consisted of 54 PTCs, among them 24 cases with distant metastases.
resultsFifty-nine percent (32/54) of analyzed PTCs were positive for at least one mutation: 27 were BRAF(+), among them eight were TERTp(+), and 1 NRAS(+), whereas five other samples harbored
conclusions
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.